cilostazol has been researched along with Pain in 7 studies
Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 8.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment." | 8.82 | The role of cilostazol in the treatment of intermittent claudication. ( Barnett, AH; Bradbury, AW; Brittenden, J; Crichton, B; Donnelly, R; Homer-Vanniasinkam, S; Mikhailidis, DP; Stansby, G, 2004) |
| "to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study." | 8.12 | Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. ( Giannoukas, A; Katsiki, N; Koufaki, P; Marakomichelakis, G; Papanas, N; Richter, D; Tentolouris, N, 2022) |
| "Renexin® is a combination pill of cilostazol and Ginkgo biloba leaf extract that is used for the improvement of ischemic symptoms associated with peripheral arterial disease (PAD)." | 5.51 | Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial. ( Ahn, SG; Ahn, TH; Chae, IH; Chang, K; Cho, DK; Cho, JM; Choi, D; Jin, HY; Kim, JH; Kim, JS; Kim, SH; Kim, SJ; Kim, SY; Kook, H; Kwon, K; Lee, HC; Lee, SR; Lim, SW; Park, CG; Yu, CW, 2022) |
| "To evaluate the safety and efficacy of cilostazol for the treatment of intermittent claudication." | 5.09 | A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. ( Beebe, HG; Bortey, EB; Cutler, BS; Dawson, DL; Forbes, WP; Herd, JA; Strandness, DE, 1999) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 4.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "This paper represents a review, by experts, of current opinion and information on intermittent claudication (IC) and the role that cilostazol plays in its treatment." | 4.82 | The role of cilostazol in the treatment of intermittent claudication. ( Barnett, AH; Bradbury, AW; Brittenden, J; Crichton, B; Donnelly, R; Homer-Vanniasinkam, S; Mikhailidis, DP; Stansby, G, 2004) |
| "to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study." | 4.12 | Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease. ( Giannoukas, A; Katsiki, N; Koufaki, P; Marakomichelakis, G; Papanas, N; Richter, D; Tentolouris, N, 2022) |
| "The key areas of treatment focus on smoking cessation, exercise rehabilitation, with supervised therapy if possible, cardiovascular risk prevention with antiplatelet drugs, statins and angiotensin converting enzymes, and correction of atherosclerotic risk factors with well-defined targets (LDL less than 1g/L, HDL greater than 0." | 2.45 | [Peripheral arterial disease with lower limb claudication: Medical treatment]. ( Bui, HT; Hadj Henni, A; Journet, J; Long, A, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Kook, H | 1 |
| Yu, CW | 1 |
| Choi, D | 1 |
| Ahn, TH | 1 |
| Chang, K | 1 |
| Cho, JM | 1 |
| Kim, SJ | 1 |
| Park, CG | 1 |
| Cho, DK | 1 |
| Kim, SH | 1 |
| Lee, HC | 1 |
| Jin, HY | 1 |
| Chae, IH | 1 |
| Kwon, K | 1 |
| Ahn, SG | 1 |
| Kim, JH | 1 |
| Lee, SR | 1 |
| Kim, JS | 1 |
| Kim, SY | 1 |
| Lim, SW | 1 |
| Katsiki, N | 1 |
| Tentolouris, N | 1 |
| Marakomichelakis, G | 1 |
| Richter, D | 1 |
| Giannoukas, A | 1 |
| Koufaki, P | 1 |
| Papanas, N | 1 |
| Long, A | 1 |
| Bui, HT | 1 |
| Journet, J | 1 |
| Hadj Henni, A | 1 |
| Stevens, JW | 1 |
| Simpson, E | 1 |
| Harnan, S | 1 |
| Squires, H | 1 |
| Meng, Y | 1 |
| Thomas, S | 1 |
| Michaels, J | 1 |
| Stansby, G | 2 |
| Asplund, CA | 1 |
| O'Connor, FG | 1 |
| Barnett, AH | 1 |
| Bradbury, AW | 1 |
| Brittenden, J | 1 |
| Crichton, B | 1 |
| Donnelly, R | 1 |
| Homer-Vanniasinkam, S | 1 |
| Mikhailidis, DP | 1 |
| Beebe, HG | 1 |
| Dawson, DL | 1 |
| Cutler, BS | 1 |
| Herd, JA | 1 |
| Strandness, DE | 1 |
| Bortey, EB | 1 |
| Forbes, WP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group and Phase III Clinical Trial to Evaluate in Efficacy and Safety of SID142 in Patients With Chronic Artery Occlusive Disease[NCT03318276] | Phase 3 | 170 participants (Actual) | Interventional | 2017-02-20 | Completed | ||
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)[NCT03883412] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
3 reviews available for cilostazol and Pain
| Article | Year |
|---|---|
[Peripheral arterial disease with lower limb claudication: Medical treatment].
Topics: Aged; Antihypertensive Agents; Arteriosclerosis; Cilostazol; Comorbidity; Diabetes Complications; Dr | 2009 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pain; Pentoxifylline; Peripheral Vascular D | 2012 |
The role of cilostazol in the treatment of intermittent claudication.
Topics: Algorithms; Arteriosclerosis; Cilostazol; Clinical Trials as Topic; Humans; Intermittent Claudicatio | 2004 |
2 trials available for cilostazol and Pain
| Article | Year |
|---|---|
Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial.
Topics: Cilostazol; Double-Blind Method; Humans; Pain; Peripheral Arterial Disease; Plant Extracts; Treatmen | 2022 |
A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
Topics: Adult; Aged; Cilostazol; Double-Blind Method; Exercise Test; Female; Humans; Intermittent Claudicati | 1999 |
2 other studies available for cilostazol and Pain
| Article | Year |
|---|---|
Real world data from a multi-centre study on the effects of cilostazol on pain symptoms and walking distance in patients with peripheral arterial disease.
Topics: Aged; Cilostazol; Female; Humans; Intermittent Claudication; Male; Middle Aged; Pain; Peripheral Art | 2022 |
An unusual cause of exertional leg pain.
Topics: Adult; Anticoagulants; Antihypertensive Agents; Cilostazol; Drug Therapy, Combination; Femoral Arter | 2004 |